Oral histone deacetylase inhibitor tucidinostat ( HBI ‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results

Cancer Science(2022)

Cited 0|Views4
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined